(Reuters) -Life sciences firm Agilent Technologies on Monday beat fourth-quarter revenue estimates, helped by strong demand for medical tools and equipment used in lab research and diagnostic services.
The laboratory equipment maker also forecast revenue for financial year 2026, which started in November, slightly ahead of Wall Street expectations.
Agilent sees 2026 revenue to be between $7.3 billion and $7.4 billion, the midpoint of which is ahead of average analyst estimates of $7.30 billion, according to data compiled by LSEG.
Medical equipment makers have seen renewed demand for contract research and diagnostics services, as pharmaceutical companies accelerate drug development in the U.S. amid President Donald Trump’s shifting trade policies.
The company’s fourth-quarter revenue came in at $1.86 billion, beating estimates of $1.83 billion.
Sales in its life sciences and diagnostics segment were at $755 million, beating the estimate of $718 million, while revenue from its CrossLab unit, which offers products and services for laboratory management, rose 7% to $775 million.
Its adjusted profit for the quarter ended October 31 was $1.59 per share compared to estimates of $1.58 per share.
(Reporting by Bageshri Banerjee in Bengaluru; Editing by Leroy Leo)
Comments